Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. Executive Chairman of the Board Michael H. Tardugno reported a routine equity compensation grant and an update to his indirect holdings. He received 4,089 shares of common stock at $2.06 per share, granted in lieu of cash for base salary, bringing his direct holdings to 12,838 shares. A separate entry shows 4,622 shares of common stock held indirectly in an IRA after shares were rolled over from a 401(k) plan. The filing shows no open-market purchases or sales and no derivative positions.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. President and CEO Stacy Lindborg received additional equity compensation. On June 5, she was granted 1,593 shares of Imunon common stock at $2.06 per share, described as stock granted in lieu of cash for a portion of her base salary.
Following this grant, Lindborg directly holds 5,235 common shares. She also has an indirect holding of 778 common shares through a 401(k) Plan. These are compensation-related awards rather than open-market purchases or sales.
Imunon, Inc. entered into a $10 million structured financing with Streeterville Capital that combines non-convertible preferred stock and secured promissory notes to support its clinical programs. The company issued 250 Series A Preferred shares at $10,000 each for $2.5 million and two secured notes with principal amounts of $2.72 million and $5 million. Imunon received $10 million at closing, placing $5 million in a cash collateral account securing the notes and retaining $5 million for corporate uses, including research and development, capital expenditures and working capital. The notes carry interest of 8% and 5%, mature in 18 months, include monthly redemption and prepayment features, and are secured by substantially all company assets other than intellectual property. The Series A Preferred Stock has a stated value of $12,000 per share with an 8% annual return, no conversion to common stock, limited voting rights, and company and holder redemption rights with premiums and default step-ups.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. Executive Chairman Michael H. Tardugno reported a compensation-related stock grant. He received 3,484 shares of Common Stock as a grant or award at $2.20 per share, described as stock granted in lieu of cash for base salary.
After this grant, he holds 8,749 shares of Imunon Common Stock directly. Separately, an indirect entry shows 4,622 shares held through a 401(k) Plan, reflecting retirement-plan ownership rather than an open-market transaction.
Imunon, Inc. director Christine A. Pellizzari received a grant of company common stock as part of her board compensation. She was awarded 5,557 shares of common stock, valued at $2.20 per share, in lieu of a portion of her cash board fees. Following this grant, she directly holds 8,142 shares of Imunon common stock. This is a compensation-related, not open-market, acquisition of shares.
Dentzer James E reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director James E. Dentzer received a grant of 11,148 shares of Common Stock as part of his board compensation. The shares were granted on May 22, 2026 at a reference price of $2.20 per share in lieu of cash for a portion of his board fees. Following this award, Dentzer directly holds 14,963 shares of Imunon common stock.
Braun Donald P reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director Donald P. Braun received a grant of 5,011 shares of Common Stock on May 22, 2026 at a price of $2.20 per share. This was stock granted in lieu of cash for a portion of his board fees. Following this award, he directly holds 9,319 shares of Imunon common stock.
Fritz Frederick J. reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director Frederick J. Fritz received an equity grant of 10,330 shares of Common Stock at $2.20 per share. The Form 4 describes this as a grant or award, not an open-market purchase. After this transaction, he directly owns 14,097 Imunon shares.
According to the accompanying footnote, the stock was granted in lieu of cash for a portion of his board fees, making this a compensation-related award rather than a discretionary share purchase in the market.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. President and CEO Stacy Lindborg reported a stock grant of 1,491 shares of Common Stock. The shares were granted at $2.20 per share as stock in lieu of a portion of base salary, making this a compensation-related award rather than an open-market purchase.
After the grant, Lindborg directly holds 3,642 shares of Imunon common stock and indirectly holds 778 shares through a 401(k) plan. The filing does not show any open-market buying or selling activity.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing beneficial ownership of 396,718 shares of Imunon, Inc. common stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power via an Investment Management Agreement.